In utero transplantation of fetal liver stem cells into human fetuses.
Based on our experience in the field of fetal liver transplantation (FLT) that we have developed since 1976, we initiated, in 1988, in utero FLT into human fetuses, taking advantage of the immunologic tolerance in young fetuses. The transplants have involved fetuses suffering from various diseases at 12-28 weeks postfertilization, with 2 of the 6 cases eventually resulting in abortion. With the 4 other fetuses, a favorable outcome was observed. Three children are more than 4 years old, and they are alive and well, with evidence of engraftment, reconstitution of immunity, and partial correction of beta-thalassemia. In the fourth case, the fetus is alive and well and birth is expected soon. In utero transplantation of stem cells is a therapy with remarkable advantages: (a) tolerance induction due to immune immaturity of the host, (b) lack of graft-versus-host disease (GVHD) due to immaturity of the donor, (c) ideal isolation of the fetus in the maternal uterus, and (d) optimal environment for donor fetal cell development in the vicinity of host fetal cells and growth factors.
Touraine
J L
JL
Department of Transplantation & Clinical Immunology, Hôpital Edouard Herriot, Lyon, France.
D000022:Abortion, Spontaneous; D002675:Child, Preschool; D005260:Female; D016332:Fetal Tissue Transplantation; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007108:Immune Tolerance; D016031:Liver Transplantation; D008661:Metabolism, Inborn Errors / Q000196:embryology* / Q000628:therapy; D011247:Pregnancy; D011256:Pregnancy Outcome; D016511:Severe Combined Immunodeficiency / Q000196:embryology* / Q000628:therapy; D017086:beta-Thalassemia / Q000196:embryology* / Q000628:therapy